| scholarly article | Q13442814 |
| P50 | author | John R. Mascola | Q63302442 |
| George M. Shaw | Q78514357 | ||
| Mark K. Louder | Q87913394 | ||
| Richard T. Wyatt | Q96247131 | ||
| P2093 | author name string | Mark Connors | |
| Xueling Wu | |||
| Stephen A Migueles | |||
| Brent Welcher | |||
| Krisha Svehla | |||
| Yuxing Li | |||
| Adhuna Phogat | |||
| P2860 | cites work | The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 |
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | Q27629806 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 | Q30431941 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. | Q36600380 | ||
| Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding | Q36795606 | ||
| Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity | Q36797873 | ||
| Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120 | Q42129803 | ||
| Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors | Q78342521 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1032-1034 | |
| P577 | publication date | 2007-08-26 | |
| P1433 | published in | Nature medicine | Q1633234 |
| P1476 | title | Broad HIV-1 neutralization mediated by CD4-binding site antibodies | |
| P478 | volume | 13 |
| Q30379637 | 25 years of HIV research! ... and what about a vaccine? |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q39537121 | A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. |
| Q39733091 | A covalent HIV vaccine: is there hope for the future? |
| Q28743092 | A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein |
| Q36748055 | A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 |
| Q34047445 | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals |
| Q34182218 | A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins |
| Q36926701 | A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction |
| Q33522232 | A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein |
| Q34743297 | A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers |
| Q34131017 | AIDS/HIV. A boost for HIV vaccine design |
| Q35058860 | Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. |
| Q38342167 | Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop |
| Q34784825 | An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses. |
| Q28545185 | An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies |
| Q37069430 | An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site |
| Q33526340 | Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals |
| Q37033400 | Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals |
| Q33377024 | Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q33876210 | Anti-idiotypic monobodies derived from a fibronectin scaffold |
| Q27489392 | Antibodies against viruses: passive and active immunization |
| Q33759392 | Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q42738983 | Antibody-based HIV-1 vaccines: recent developments and future directions |
| Q33914185 | Antibody-secreting B cells in HIV infection |
| Q36263513 | Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. |
| Q46103391 | As Good As It Gets? The Problem of HIV Persistence despite Antiretroviral Drugs |
| Q33373664 | B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q46296261 | Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials |
| Q35774051 | Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site |
| Q37438127 | Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies |
| Q33614495 | Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables |
| Q34962766 | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals |
| Q36397394 | Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q35914292 | Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection |
| Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
| Q39084604 | CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection |
| Q94939084 | CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498 |
| Q45333913 | CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children |
| Q27026806 | Catching HIV 'in the act' with 3D electron microscopy |
| Q34229664 | Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies |
| Q38154038 | Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies |
| Q34657290 | Challenges in the development of an HIV-1 vaccine |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q33957908 | Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco |
| Q37145319 | Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor |
| Q40581381 | Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses |
| Q28749755 | Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies |
| Q33648910 | Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes |
| Q34663118 | Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques |
| Q27675190 | Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold |
| Q36827348 | Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors |
| Q34934438 | Conformational and Structural Features of HIV-1 gp120 Underlying the Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18 |
| Q43215260 | Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers |
| Q37671423 | Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities |
| Q36102252 | Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen |
| Q36105782 | Cross-reactive broadly neutralizing antibodies: timing is everything |
| Q36747750 | Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens |
| Q27662167 | Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 |
| Q34663554 | DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial |
| Q27684578 | Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization |
| Q36845632 | Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans |
| Q37163082 | Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity |
| Q36878906 | Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus |
| Q34094476 | Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies |
| Q36742228 | Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies |
| Q35060140 | Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system |
| Q36736392 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques |
| Q38081965 | Developments in virus-like particle-based vaccines for HIV. |
| Q27646554 | Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity |
| Q42850455 | Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity |
| Q33410222 | Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection |
| Q35691113 | Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization |
| Q37644030 | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q42084754 | Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. |
| Q33571825 | Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein |
| Q35101333 | Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques |
| Q35001377 | Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? |
| Q30413840 | Efficient on-chip isolation of HIV subtypes |
| Q34133551 | Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. |
| Q56994404 | Elite control of HIV infection: implications for vaccine design |
| Q34594701 | Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1 |
| Q36750045 | Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies |
| Q35070898 | Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays |
| Q35735385 | Enhanced HIV-1 neutralization by antibody heteroligation |
| Q37192171 | Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain |
| Q38979760 | Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. |
| Q50075362 | Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response |
| Q42287446 | Epitope Specificity of Cross‐Clade Neutralizing Sera from Chinese HIV‐1‐Positive Individuals |
| Q41573062 | Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies |
| Q33888559 | Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects |
| Q42959357 | Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. |
| Q34819651 | Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic |
| Q38992740 | Evolution of B cell analysis and Env trimer redesign |
| Q37254327 | Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations |
| Q34478071 | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject |
| Q34175370 | Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity |
| Q37033294 | Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection |
| Q35491705 | Feline immunodeficiency virus (FIV) neutralization: a review |
| Q50420466 | Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site |
| Q39521335 | Flow cytometry based identification of simian immunodeficiency virus Env-specific B lymphocytes |
| Q30395868 | Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. |
| Q37033269 | Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies |
| Q33558279 | Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 |
| Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
| Q38764547 | Germline-targeting immunogens |
| Q35582579 | Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses |
| Q35585401 | Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals |
| Q35173635 | HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies |
| Q28751706 | HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis |
| Q39806672 | HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase |
| Q47841328 | HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats |
| Q36276274 | HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins |
| Q56913214 | HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes |
| Q36583109 | HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation |
| Q33552488 | HIV-1 and influenza antibodies: seeing antigens in new ways |
| Q45765336 | HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients. |
| Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
| Q34399542 | HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile |
| Q33947008 | HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 |
| Q37073506 | HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds |
| Q35640998 | HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q89746983 | HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice |
| Q33869882 | HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies |
| Q27324184 | HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization |
| Q33642318 | HIV-1 vaccine development after STEP. |
| Q40159913 | HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection |
| Q27000480 | HIV‐1 neutralizing antibodies: understanding nature's pathways |
| Q33812812 | Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant |
| Q33920519 | High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz |
| Q37471315 | High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination |
| Q35826509 | High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection |
| Q37735822 | High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q42228026 | Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. |
| Q42212856 | Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4. |
| Q39250593 | How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design |
| Q34096475 | Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q37033291 | Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. |
| Q36994644 | Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses |
| Q37051645 | Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma |
| Q37026347 | Human monoclonal antibodies by immortalization of memory B cells |
| Q36171536 | Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. |
| Q34412302 | Identification and Characterization of a Broadly Cross-Reactive HIV-1 Human Monoclonal Antibody That Binds to Both gp120 and gp41 |
| Q35592911 | Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual |
| Q88582157 | Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses |
| Q34488183 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library |
| Q34428738 | Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. |
| Q38950134 | Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q36066341 | Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor |
| Q30353709 | Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. |
| Q35667479 | Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein |
| Q37729781 | Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. |
| Q36804634 | Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination |
| Q34937404 | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth |
| Q37252966 | Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization |
| Q33614605 | Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates |
| Q34848486 | Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia |
| Q33696406 | Isolation of Potent Neutralizing Monoclonal Antibodies from an SIV-Infected Rhesus Macaque by Phage Display |
| Q40331435 | JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. |
| Q36888400 | Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor |
| Q37245921 | Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes |
| Q37910841 | Limitations to the structure‐based design of HIV‐1 vaccine immunogens |
| Q35077797 | Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies |
| Q36309003 | Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection |
| Q36239578 | Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting |
| Q36444787 | Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection |
| Q36862088 | Maturational characteristics of HIV-specific antibodies in viremic individuals |
| Q35192782 | Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 |
| Q37410770 | Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment |
| Q34023249 | Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses |
| Q36127736 | MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency |
| Q36781872 | Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains |
| Q36978277 | Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure |
| Q36568026 | Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies |
| Q27679353 | Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies |
| Q36099045 | N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization |
| Q34594978 | N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function |
| Q35864051 | N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03 |
| Q30436026 | Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood |
| Q45358429 | Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization |
| Q89548775 | Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization |
| Q40909337 | Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q34550046 | Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success |
| Q33887693 | Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? |
| Q37519312 | Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? |
| Q33807535 | Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay |
| Q34344323 | New templates for HIV-1 antibody-based vaccine design |
| Q35275117 | Newcastle Disease Virus Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces Strong Mucosal and Serum Antibody Responses in Guinea Pigs |
| Q37417794 | Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens |
| Q27675468 | Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q34185625 | Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. |
| Q37189179 | Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q34284855 | Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization |
| Q64080897 | Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus |
| Q28749120 | Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses |
| Q36384117 | Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors |
| Q33749827 | Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies |
| Q39315316 | Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B′-infected former plasma donors from China naïve to antiretroviral therapy |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q35137125 | Progress in the rational design of an AIDS vaccine |
| Q30379200 | Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). |
| Q51830138 | Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. |
| Q33614461 | Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites |
| Q36559735 | Proteolytic Processing of the Human Immunodeficiency Virus Envelope Glycoprotein Precursor Decreases Conformational Flexibility |
| Q40325417 | Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer |
| Q39610645 | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 |
| Q91960739 | Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan |
| Q35647701 | Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque |
| Q29619511 | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 |
| Q35603504 | Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. |
| Q34539819 | Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs |
| Q34042642 | Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections |
| Q33676600 | Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region |
| Q64103612 | Relative Binding Affinity Prediction of Charge-Changing Sequence Mutations with FEP in Protein-Protein Interfaces |
| Q45365167 | Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence |
| Q56993265 | Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development |
| Q34225659 | Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine |
| Q37336704 | Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q41019767 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults |
| Q35943521 | Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site |
| Q27670829 | Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding |
| Q34397758 | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies |
| Q34982715 | Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies |
| Q34456367 | Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China |
| Q34096530 | Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates |
| Q36231944 | Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q27663293 | Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 |
| Q27658449 | Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 |
| Q27643993 | Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q52338073 | Structure and Immune Recognition of the HIV Glycan Shield |
| Q27662155 | Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 |
| Q39602726 | Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers |
| Q40438707 | Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies |
| Q34987048 | Structure-based Vaccine Design in HIV: Blind Men and the Elephant? |
| Q33972838 | Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry |
| Q27316899 | Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site |
| Q38811547 | Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting |
| Q34312037 | Superinfection by Discordant Subtypes of HIV-1 Does Not Enhance the Neutralizing Antibody Response against Autologous Virus |
| Q59356767 | T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection |
| Q37246321 | Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies |
| Q37179763 | Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding |
| Q33664910 | Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response |
| Q64062652 | The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization |
| Q33504607 | The cat and mouse of HIV-1 antibody escape |
| Q30367176 | The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. |
| Q36404101 | The changing face of HIV vaccine research |
| Q38019332 | The design and evaluation of HIV-1 vaccines |
| Q36155396 | The development of CD4 binding site antibodies during HIV-1 infection |
| Q26801603 | The evolution within us |
| Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
| Q38192357 | The past, present and future of neutralizing antibodies for hepatitis C virus |
| Q83601568 | The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine? |
| Q37667360 | Thirty years of the human immunodeficiency virus epidemic and beyond |
| Q42185150 | Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. |
| Q33614365 | Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies |
| Q37431843 | Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity |
| Q33854841 | Transplanting supersites of HIV-1 vulnerability |
| Q38810452 | Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design |
| Q35076664 | Two Closely Related Env Antigens from the Same Patient Elicited Different Spectra of Neutralizing Antibodies against Heterologous HIV-1 Isolates |
| Q33826682 | Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain |
| Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
| Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
| Q37295534 | Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.